Skip to main content
RKDA logo

RKDA · Arcadia Biosciences, Inc.

Track RKDA — free
$0.17 -0.02 (-9.90%) At close · Nov 19
Market Cap
$1.03M
Shares
6.07M
Volume · Nov 19 499.11K Avg daily vol (3M) 2.27M

Price & Indicators

 

Key stats

Close
$0.17
Open
$0.19
Day range
$0.17–0.21
52-week closing range
$0.15–3.84
Average volume, 30 days
3.1M
Short interest
116K · 1.9% of shares · 1.0 days
Short volume, last session
50%
Last earnings
Nov 7, 2025
Latest filing
10-Q · Nov 12
Price history
Jan 2020 to Nov 2026

Up next

call held May 8, 2025

Latest documents

2026
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises, but going-concern uncertainty and material weaknesses remain

Arcadia reported nine-month product revenue growth of $205,000, or 5%, but a net loss of $8.9 million and cash of $2.8 million. Management raised substantial doubt about its going-concern status and disclosed material weaknesses in financial controls.

Revenue $1.62M ▲ 24.3% Net income $1.76M ▲ 105.0% Diluted EPS $0.29 ▼ 53.2%
Read from the MD&A section
5 source passages
Arcadia has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Product revenues increased $205,000, or 5%, during the nine months ended September 30, 2026 compared to the same period in 2025 driven by strong volumes during the third quarter of 2026 that more than offset the slower growth during the first half of 2026 due to inventory delays. As of September 30, 2026, we had cash and cash equivalents of $2.8 million. For the nine months ended September 30, 2026, the Company had net loss of $8.9 million and net cash used in operations of $2.7 million. We believe that our existing cash and cash equivalents will not be sufficient to meet our anticipated cash requirements for at least the next 12 months from the issuance date of these condensed consolidated financial statements, which raises substantial doubt about the Company’s ability to continue as a going concern. In connection with our evaluations for the year ended December 31, 2025, and for the three and nine months ended September 30, 2026, we identified material weaknesses in our internal control over financial reporting related to: (a) insufficient segregation of duties in the financial statement close process; and (b) insufficient information system controls, including access and change management controls. Open the document at this passage
Nov 12
Current report 8-K
Zola revenue rises 24% to record quarterly sales

Arcadia Biosciences reported Zola third-quarter 2026 revenue growth of 24% year over year and record quarterly sales, with net income of $1.8 million. A new 1L espresso formulation ships this month, while slim cans launch in early 2027.

Financial results
4 source passages
Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights -- Zola® Q3 revenues increase 24% year-over-year, largest quarterly sales ever -- Net income attributable to common stockholders for the third quarter of 2026 was $1.8 million, or $0.29 per share, a $900,000 improvement from $856,000 net income, or $0.63 per share, for the third quarter of 2025. -- New 1L espresso formulation ships this month, slim cans to launch in early 2027 -- Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.06M
Trailing 12 months
Net income (TTM)
−$10.19M
Trailing 12 months
Revenue growth YoY
+24.3%
Year over year
Operating margin
-69.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+342.1%
Year over year · more shares
Price change (1Y)
-95.3%
Trailing year
Short interest
1.9%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −81%
below
Price vs 50-day avg −33%
below
RSI (14) 40
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +5%
trailing
6-month return −82%
trailing
YTD return −91%
this year
Relative strength −76%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.91% of shares out · ▼ -66.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
19 holders — near 3-yr high, broad support
Squeeze score 37
low risk · 0–100
Fundamentals
Weak
Revenue growth −4%
Y/Y
EPS growth +67%
Y/Y
Free cash flow $-4.7M
Quant / Vol
risk profile
Very High
Volatility 104%
annualized · 1-yr
Max drawdown −96%
past year
ATR 21.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jul 20, 2023
Annual operating expense savings · starting in August 2023 $3M – $4M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−81% Bearish
Price vs 50-day avg
−33% Bearish
RSI (14)
40 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.91% of shares out · ▼ -66.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
19 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $0 · 1% Range high $4
vs 200-day avg -81% vs 50-day avg -33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Packaged Foods — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RKDA
Arcadia Biosciences, Inc.
this stock
$1.03M -91.5% -3.7% — 1.9%
JBS
Jbs N.V.
$39.01B -17.8% — — 1.3%
KHC
Kraft Heinz Co
$29.50B +2.8% -0.1% — 8.7%
GIS
General Mills Inc
$18.44B -25.8% +4.1% — 7.0%
SJM
J M SMUCKER Co
$14.02B +34.2% +3.7% — 2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
19
% held
10.2%
Net QoQ
+407.3K sh
Top holder
ARMISTICE CAPITAL, LLC
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Falling
Shares short
115.6K
Days to cover
1.0d
Change
-227.3K sh
View
Short Volume
Short vol %
50%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
3.6K
Value
$606
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
56.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$4.9M
Net income (FY)
$-2.3M
EPS diluted
$-1.71
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
22

Arcadia reported nine-month product revenue growth of $205,000, or 5%, but a net loss of $8.9 million and cash of $2.8 million. Management raised substantial doubt about its going-concern status and disclosed material weaknesses in financial controls.

View
Exempt Offerings
Offering
$11.4M
Filed
Jun 26, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 7, 2025
View
Investor Relations
Latest news
Arcadia Biosciences (RKDA) Announ…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
RKDA -23.8% +4.6% -81.5% +7.2% -91.5%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -18.3% +10.9% -75.9% +12.4% -96.4%
Key facts CIK 1469443 CUSIP 039014303 13F (30d) 18 filings 17 filers Visit website Investor relations